Join Growin Stock Community!

Exagen inc.XGN.US Overview

US StockHealthcare
(No presentation for XGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XGN AI Insights

XGN Overall Performance

XGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XGN Recent Performance

-3.94%

Exagen inc.

-3.61%

Avg of Sector

-2.16%

S&P500

XGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XGN Key Information

XGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XGN Profile

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Price of XGN

XGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.29
PB Ratio
4.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
59.86%
Net Margin
-29.94%
Revenue Growth (YoY)
14.08%
Profit Growth (YoY)
16.14%
3-Year Revenue Growth
5.40%
3-Year Profit Growth
4.95%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.84
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.29
PB Ratio
4.51
Price-to-FCF
-
Gross Margin
59.86%
Net Margin
-29.94%
Revenue Growth (YoY)
14.08%
Profit Growth (YoY)
16.14%
3-Year Revenue Growth
5.40%
3-Year Profit Growth
4.95%

  • When is XGN's latest earnings report released?

    The most recent financial report for Exagen inc. (XGN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XGN's short-term business performance and financial health. For the latest updates on XGN's earnings releases, visit this page regularly.

  • What is the operating profit of XGN?

    According to the latest financial report, Exagen inc. (XGN) reported an Operating Profit of -3.1M with an Operating Margin of -17.98% this period, representing a growth of 33.52% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is XGN's revenue growth?

    In the latest financial report, Exagen inc. (XGN) announced revenue of 17.24M, with a Year-Over-Year growth rate of 37.87%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does XGN have?

    As of the end of the reporting period, Exagen inc. (XGN) had total debt of 28.17M, with a debt ratio of 0.45. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does XGN have?

    At the end of the period, Exagen inc. (XGN) held Total Cash and Cash Equivalents of 35.65M, accounting for 0.57 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does XGN go with three margins increasing?

    In the latest report, Exagen inc. (XGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 58.4%%, operating margin of -17.98%%, and net margin of -41.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess XGN's profit trajectory and future growth potential.

  • Is XGN's EPS continuing to grow?

    According to the past four quarterly reports, Exagen inc. (XGN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of XGN?

    Exagen inc. (XGN)'s Free Cash Flow (FCF) for the period is 2.67M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 214.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.